{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:42:28Z","timestamp":1756809748220},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10,1]]},"DOI":"10.2146\/ajhp090516","type":"journal-article","created":{"date-parts":[[2010,9,17]],"date-time":"2010-09-17T18:10:46Z","timestamp":1284747046000},"page":"1611-1614","source":"Crossref","is-referenced-by-count":6,"title":["Decreased plasma efavirenz concentrations in a patient receiving rifabutin"],"prefix":"10.1093","volume":"67","author":[{"given":"Oliver","family":"Hsu","sequence":"first","affiliation":[{"name":"University of California San Francisco, San Francisco; at the time of writing he was pharmacy student, PACE Clinic, San Jose, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine J.","family":"Hill","sequence":"additional","affiliation":[{"name":"Santa Clara Valley Health and Hospital Systems, San Jose, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, University of California San Francisco (UCSF), San Francisco."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benny","family":"Tan","sequence":"additional","affiliation":[{"name":"CVS\/Pharmacy, Milpitas, CA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"O\u2019Brien","sequence":"additional","affiliation":[{"name":"School of Pharmacy, UCSF, and HIV Pharmacist Specialist, Santa Clara Valley Health and Hospital Systems"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041104314334200_b1-0671611","first-page":"1","volume-title":"Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2009"},{"key":"key\n\t\t\t\t2019041104314334200_b2-0671611","volume-title":"Sustiva (efavirenz) package insert","year":"2009"},{"key":"key\n\t\t\t\t2019041104314334200_b3-0671611","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1086\/343047","article-title":"Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak","volume":"35","author":"Spradling","year":"2002","journal-title":"Clin Infec Dis"},{"key":"key\n\t\t\t\t2019041104314334200_b4-0671611","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/00007691-200406000-00008","article-title":"Efavirenz plasma concentrations in HIV-infected patients: inter- and intra individual variability and clinical effects","volume":"26","author":"Stahle","year":"2004","journal-title":"Ther Drug Monit"},{"key":"key\n\t\t\t\t2019041104314334200_b5-0671611","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2165\/00003088-200039030-00003","article-title":"Drug-drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease","volume":"39","author":"Kuper","year":"2000","journal-title":"Clin Pharmacokinet"},{"key":"key\n\t\t\t\t2019041104314334200_b6-0671611","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1345\/aph.1H423","article-title":"New tool to evaluate drug interactions","volume":"41","author":"Horn","year":"2007","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t2019041104314334200_b7-0671611","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1086\/497835","article-title":"Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring","volume":"41","author":"Gutierrez","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041104314334200_b8-0671611","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1 infected patient","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"key\n\t\t\t\t2019041104314334200_b9-0671611","first-page":"551","article-title":"Therapeutic drug monitoring of efavirenz: trough levels cannot be estimated on the basis of earlier plasma determinations","volume":"39","author":"Lopez-Cortes","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019041104314334200_b10-0671611","first-page":"4","article-title":"Updated guideline to perform therapeutic drug monitoring for antiretroviral agents","volume":"3","author":"La Porte","year":"2006","journal-title":"Rev Antivir Ther"},{"key":"key\n\t\t\t\t2019041104314334200_b11-0671611","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1128\/AAC.40.12.2721","article-title":"Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS","volume":"40","author":"Balfour","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t2019041104314334200_b12-0671611","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1093\/infdis\/172.1.225","article-title":"Foscarnet decreases human immunodeficiency virus RNA","volume":"172","author":"Kaiser","year":"1995","journal-title":"J Infect Dis"},{"issue":"suppl 1","key":"key\n\t\t\t\t2019041104314334200_b13-0671611","article-title":"Efavirenz, rifampicin and rifabutin\u2014a case for therapeutic drug monitoring?","volume":"8","author":"Lewthwaite","year":"2003","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t2019041104314334200_b14-0671611","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1086\/496980","article-title":"Evaluation of the drug interaction between rifabutin and efavirenz in patients with HIV infection and tuberculosis","volume":"41","author":"Weiner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t2019041104314334200_b15-0671611","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1093\/jac\/dkl357","article-title":"Efavirenz trough levels are not associated with virological failure throughout therapy with 800 mg daily and rifampicin-containing antituberculosis regimen","volume":"58","author":"Lopez-Cortes","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t2019041104314334200_b16-0671611","doi-asserted-by":"crossref","article-title":"Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms","author":"Lindfelt","DOI":"10.1345\/aph.1P141"},{"key":"key\n\t\t\t\t2019041104314334200_b17-0671611","volume-title":"Intelence (etravirine) package insert","year":"2009"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/67\/19\/1611\/28345313\/ajhp1611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T18:01:17Z","timestamp":1559671277000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/67\/19\/1611\/5130741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,1]]},"references-count":17,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2010,10,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp090516","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2010,10,1]]},"published":{"date-parts":[[2010,10,1]]}}}